Cargando…

Greater improvement in LRRK2 G2019S patients undergoing Subthalamic Nucleus Deep Brain Stimulation compared to non-mutation carriers

BACKGROUND: Bilateral subthalamic nucleus deep brain stimulation (STN-DBS) of parkinson’s disease (PD) patients has demonstrated to improve motor performance and to reduce dopa-induced dyskinesia. An association between the occurrence of dyskinesias and LRRK2 (leucine-rich repeat kinase 2) G2019S ge...

Descripción completa

Detalles Bibliográficos
Autores principales: Sayad, Massiva, Zouambia, Mohamed, Chaouch, Malika, Ferrat, Farida, Nebbal, Mustapha, Bendini, Mohamed, Lesage, Suzanne, Brice, Alexis, Brahim Errahmani, Mohamed, Asselah, Boualem
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4736184/
https://www.ncbi.nlm.nih.gov/pubmed/26831335
http://dx.doi.org/10.1186/s12868-016-0240-4
_version_ 1782413227638915072
author Sayad, Massiva
Zouambia, Mohamed
Chaouch, Malika
Ferrat, Farida
Nebbal, Mustapha
Bendini, Mohamed
Lesage, Suzanne
Brice, Alexis
Brahim Errahmani, Mohamed
Asselah, Boualem
author_facet Sayad, Massiva
Zouambia, Mohamed
Chaouch, Malika
Ferrat, Farida
Nebbal, Mustapha
Bendini, Mohamed
Lesage, Suzanne
Brice, Alexis
Brahim Errahmani, Mohamed
Asselah, Boualem
author_sort Sayad, Massiva
collection PubMed
description BACKGROUND: Bilateral subthalamic nucleus deep brain stimulation (STN-DBS) of parkinson’s disease (PD) patients has demonstrated to improve motor performance and to reduce dopa-induced dyskinesia. An association between the occurrence of dyskinesias and LRRK2 (leucine-rich repeat kinase 2) G2019S gene mutations has recently been suggested. The aim of this study is to discover the impact of the G2019S mutation (with high incidence in the authors’ native Algeria) on the symptom response of PD in patients who underwent STN-DBS. METHODS: We carried out a comparative statistical study for the clinical evaluation and neuropsychological assessment of 27 Algerian PD STN-DBS patients, both G2019S mutation carriers (MC) and non-carriers (NC). A multiple correspondence analysis (MCA) was then conducted to compare the results with those from groups of individuals with similar modalities. RESULTS: The MCA revealed that MC and NC PD patients showed two different patterns of clinical evaluations. The group of idiopathic patients showed some differences compared to the clinical evaluations, depending on gender. No association was found between the G2019S mutation and the Mini Mental State Examination scores (MMSE), and MC patients appeared more susceptible to dyskinesia than NC patients. In NC patients, we found two cases with Parkin mutations who had a different “honeymoon” period and different initial symptoms. The results showed considerable improvement of motor unified parkinson’s disease rating scale III (UPDRS-III) in a situation of stimulation without medication in the MC patients with a percentage of improvement (51.1 %) over the required 30 % compared to the NC patients (25.5 %). The same result was observed for the Schwab and England’s activities of daily living scale (S and E scale), which thus demonstrated a greater effectiveness of DBS for MC patients than for NC patients. However, the Hoehn and Yahr scale (H and Y Scale) showed the same significance in a situation of stimulation for MC and NC patients. In this later group, the best scores of UPDRS-III were observed for patients with the Parkin mutation before they underwent surgery. CONCLUSIONS: This study shows that surgical treatment probably has a more significant impact on LRRK2 G2019S MC than on idiopathic patients.
format Online
Article
Text
id pubmed-4736184
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-47361842016-02-03 Greater improvement in LRRK2 G2019S patients undergoing Subthalamic Nucleus Deep Brain Stimulation compared to non-mutation carriers Sayad, Massiva Zouambia, Mohamed Chaouch, Malika Ferrat, Farida Nebbal, Mustapha Bendini, Mohamed Lesage, Suzanne Brice, Alexis Brahim Errahmani, Mohamed Asselah, Boualem BMC Neurosci Research Article BACKGROUND: Bilateral subthalamic nucleus deep brain stimulation (STN-DBS) of parkinson’s disease (PD) patients has demonstrated to improve motor performance and to reduce dopa-induced dyskinesia. An association between the occurrence of dyskinesias and LRRK2 (leucine-rich repeat kinase 2) G2019S gene mutations has recently been suggested. The aim of this study is to discover the impact of the G2019S mutation (with high incidence in the authors’ native Algeria) on the symptom response of PD in patients who underwent STN-DBS. METHODS: We carried out a comparative statistical study for the clinical evaluation and neuropsychological assessment of 27 Algerian PD STN-DBS patients, both G2019S mutation carriers (MC) and non-carriers (NC). A multiple correspondence analysis (MCA) was then conducted to compare the results with those from groups of individuals with similar modalities. RESULTS: The MCA revealed that MC and NC PD patients showed two different patterns of clinical evaluations. The group of idiopathic patients showed some differences compared to the clinical evaluations, depending on gender. No association was found between the G2019S mutation and the Mini Mental State Examination scores (MMSE), and MC patients appeared more susceptible to dyskinesia than NC patients. In NC patients, we found two cases with Parkin mutations who had a different “honeymoon” period and different initial symptoms. The results showed considerable improvement of motor unified parkinson’s disease rating scale III (UPDRS-III) in a situation of stimulation without medication in the MC patients with a percentage of improvement (51.1 %) over the required 30 % compared to the NC patients (25.5 %). The same result was observed for the Schwab and England’s activities of daily living scale (S and E scale), which thus demonstrated a greater effectiveness of DBS for MC patients than for NC patients. However, the Hoehn and Yahr scale (H and Y Scale) showed the same significance in a situation of stimulation for MC and NC patients. In this later group, the best scores of UPDRS-III were observed for patients with the Parkin mutation before they underwent surgery. CONCLUSIONS: This study shows that surgical treatment probably has a more significant impact on LRRK2 G2019S MC than on idiopathic patients. BioMed Central 2016-02-01 /pmc/articles/PMC4736184/ /pubmed/26831335 http://dx.doi.org/10.1186/s12868-016-0240-4 Text en © Sayad et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Sayad, Massiva
Zouambia, Mohamed
Chaouch, Malika
Ferrat, Farida
Nebbal, Mustapha
Bendini, Mohamed
Lesage, Suzanne
Brice, Alexis
Brahim Errahmani, Mohamed
Asselah, Boualem
Greater improvement in LRRK2 G2019S patients undergoing Subthalamic Nucleus Deep Brain Stimulation compared to non-mutation carriers
title Greater improvement in LRRK2 G2019S patients undergoing Subthalamic Nucleus Deep Brain Stimulation compared to non-mutation carriers
title_full Greater improvement in LRRK2 G2019S patients undergoing Subthalamic Nucleus Deep Brain Stimulation compared to non-mutation carriers
title_fullStr Greater improvement in LRRK2 G2019S patients undergoing Subthalamic Nucleus Deep Brain Stimulation compared to non-mutation carriers
title_full_unstemmed Greater improvement in LRRK2 G2019S patients undergoing Subthalamic Nucleus Deep Brain Stimulation compared to non-mutation carriers
title_short Greater improvement in LRRK2 G2019S patients undergoing Subthalamic Nucleus Deep Brain Stimulation compared to non-mutation carriers
title_sort greater improvement in lrrk2 g2019s patients undergoing subthalamic nucleus deep brain stimulation compared to non-mutation carriers
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4736184/
https://www.ncbi.nlm.nih.gov/pubmed/26831335
http://dx.doi.org/10.1186/s12868-016-0240-4
work_keys_str_mv AT sayadmassiva greaterimprovementinlrrk2g2019spatientsundergoingsubthalamicnucleusdeepbrainstimulationcomparedtononmutationcarriers
AT zouambiamohamed greaterimprovementinlrrk2g2019spatientsundergoingsubthalamicnucleusdeepbrainstimulationcomparedtononmutationcarriers
AT chaouchmalika greaterimprovementinlrrk2g2019spatientsundergoingsubthalamicnucleusdeepbrainstimulationcomparedtononmutationcarriers
AT ferratfarida greaterimprovementinlrrk2g2019spatientsundergoingsubthalamicnucleusdeepbrainstimulationcomparedtononmutationcarriers
AT nebbalmustapha greaterimprovementinlrrk2g2019spatientsundergoingsubthalamicnucleusdeepbrainstimulationcomparedtononmutationcarriers
AT bendinimohamed greaterimprovementinlrrk2g2019spatientsundergoingsubthalamicnucleusdeepbrainstimulationcomparedtononmutationcarriers
AT lesagesuzanne greaterimprovementinlrrk2g2019spatientsundergoingsubthalamicnucleusdeepbrainstimulationcomparedtononmutationcarriers
AT bricealexis greaterimprovementinlrrk2g2019spatientsundergoingsubthalamicnucleusdeepbrainstimulationcomparedtononmutationcarriers
AT brahimerrahmanimohamed greaterimprovementinlrrk2g2019spatientsundergoingsubthalamicnucleusdeepbrainstimulationcomparedtononmutationcarriers
AT asselahboualem greaterimprovementinlrrk2g2019spatientsundergoingsubthalamicnucleusdeepbrainstimulationcomparedtononmutationcarriers